At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 44,247 enrolled
Drug / intervention
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older
In Brief
A Phase 3 clinical trial evaluating Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) and Placebo for COVID-19. Completed, enrolled 44,247 participants across 74 sites in 5 countries.
Detailed Summary
This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesArgentina, Chile, Mexico, Pakistan, Russia
CollaboratorsBeijing Institute of Biotechnology
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionAug 2021
Study CompletionOct 2022
TodayJul 2026
First PostedAug 26, 2020
Enrollment StartSep 15, 2020
Primary CompletionAug 7, 2021
Study CompletionOct 21, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.9 years ago
Interventions
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)biological
Intramuscular administration
Placebobiological
Intramuscular administration